Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat

Experimental Neurology

Volumn 155, Issue 2, 1999, Pages 204-220

  Henry, Brian ^a   Crossman, Alan R ^a   Brotchie, Jonathan M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

6 hydroxydopamine; Dynorphin; Enkephalin; In situ hybridization; L DOPA induced dyskinesia; Opioids; Parkinson's disease

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; DYNORPHIN; LEVODOPA; LISURIDE; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXIDOPAMINE; PERGOLIDE; PRAMIPEXOLE; PREPROENKEPHALIN; ROPINIROLE;

ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BEHAVIOR; CHOREA; CONFUSION; CONTROLLED STUDY; DYSKINESIA; GENE SEQUENCE; HEMIBALLISM; IMAGE ANALYSIS; INVOLUNTARY MOVEMENT; NONHUMAN; PARANOIA; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TOPOGRAPHY; VISUAL HALLUCINATION;

EID: 0033010166     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1998.6996     Document Type: Article

References (103)

1. Aellig W. H., Nuesch E. Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration in man. Int. J. Clin. Pharmacol. Biopharm. 15:1977;106-112.
2. Agid Y., Barroche G., Bonnet A. M., Javoy-Agid F., Kato G., Lhermitte F., Pollak P., Signoret J. L. Dopamine receptor stimulating agonists in the treatment of Parkinson's disease. Biomedicine. 30:1979;67-71.
3. Angulo J. A., Christoph G. R., Manning R. W., Burkhart B. A., Davis L. G. Reduction of dopamine receptor activity differentially alters striatal neuropeptide mRNA levels. Adv. Exp. Med. Biol. 221:1987;385-391.
4. Angulo J. A., Davis L. G., Burkhart B. A., Christoph G. R. Reduction of striatal dopaminergic neurotransmission elevates striatal proenkephalin mRNA. Eur. J. Pharmacol. 130:1986;341-343.
5. Arcari P., Martinelli R., Salvatore F. The complete sequence of a full length cDNA for human liver glyeraldehyde-3-phosphate dehydrogenase: Evidence for multiple mRNA species. Nucleic Acids Res. 12:1984;9179-9189.
6. Barbeau A. l. Can. Med. Assoc. J. 101:1969;791-800.
7. 3. Brain Res. 379:1986;294-299.
8. Bevan P. Repeated apomorphine treatment causes behavioural supersensitivity and dopamine D2 receptor hyposensitivity. Neurosci. Lett. 25:1983;185-189.
9. Bordet R., Ridray S., Carboni S., Diaz J., Sokoloff P., Schwartz J. C. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. USA. 94:1997;3363-3367.
10. Brooks D. J., Torjanski N., Burn D. J. Ropinirole in the symptomatic treatment of Parkinson's disease. J. Neural Trans. Suppl. 45:1995;231-238.
11. Calne D. B., Plotkin C., Williams A. C., Nutt J. G., Neophytides A., Teychenne P. F. Long-term treatment of parkinsonism with bromocriptine. Lancet. 8:1978;735-737.
12. Calne D. B., Teychenne P. F., Claveria L. E. Bromocriptine in Parkinsonism. BMJ. 4:1974;442-444.
13. Campbell K., Bjorklund A. Prefrontal corticostriatal afferents maintain increased enkephalin gene expression in the dopamine-denervated rat striatum. Eur. J. Neurosci. 6:1994;1371-1383.
14. Carey R. J. Naloxone reversesl. Life Sci. 48:1991;1303-1308.
15. Cenci M. A., Lee C. S., Bjorklund A. l. Eur. J. Neurosci. 10:1998;2694-2706.
16. Chritin M., Feuerstein C., Savasta M. Time-course of changes in striatal levels of DA uptake sites, DA D2 receptor and preproenkephalin mRNAs after nigrostriatal dopaminergic denervation in the rat. Brain Res. Mol. Brain. Res. 19:1993;318-322.
17. Civelli O., Douglass J., Goldstein A., Herbert E. Sequence and expression of the rat prodynorphin gene. Proc. Natl. Acad. Sci. USA. 82:1985;4291-4295.
18. Clarke C. E., Boyce S., Sambrook M. A., Stahl S. M., Crossman A. R. Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Naunyn Schmiedebergs Arch. Pharmacol. 338:1988;35-38.
19. Cole D. G., Kobierski L. A., Konradi C., Hyman S. E. 6-hydroxydopamine lesions of rat substantia nigra up-regulate dopamine-induced phosphorylation of the cAMP-response element-binding protein in striatal neurons. Proc. Natl. Acad. Sci. USA. 91:1994;9631-9635.
20. Colzi A., Turner K., Lees A. J. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 64:1998;573-576.
21. Cooper D. R., Marrel C., Testa B., van de Waterbeemd H., Quinn N., Jenner P., Marsden C. D. l. Clin. Neuropharmacol. 7:1984;89-98.
22. Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of parkinsonism: Chronic treatment withl. N. Engl. J. Med. 280:1969;337-345.
23. Cotzias G. C., Papavasiliou P. S., Tolosa E. S., Mendez J. S., Bell-Midura M. Treatment of Parkinson's disease with aporphines: Possible role of growth hormone. N. Engl. J. Med. 294:1976;567-572.
24. Crossman A. R. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induce dyskinesias in Parkinson's disease: Implications for future strategies in treatment. Mov. Dis. 5:1990;100-108.
25. Dolphin A. C., Jenner P., Sawaya C. B., Marsden C. D., Testa B. The effect of bromocriptine on locomotor activity and cerebral catecholamines in rodents. J. Pharm. Pharmacol. 29:1977;727-734.
26. Duty S., Brotchie J. M. Enhancement of the behavioural response to apomorphine following repeated treatment in the 6-hydroxydiopamine-lesioned rat is temporally correlated with a rise in pre-proenkephalin-B, but not pre-proenkephalin-A, gene expression. Exp. Neurol. 144:1997;423-432.
27. Duty S., Henry B., Crossman A. R., Brotchie J. M. Topographical organisation of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat. Exp. Neurol. 150:1998;233-234.
28. Engber T. M., Susel Z., Kuo S., Gerfen C. R., Chase T. N. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output neurons of 6-hydroxydopamine lesioned rats. Brain Res. 552:1991;113-118.
29. Freedman S. B., Patel S., Marwood R., Emms F., Seabrook G. R., Knowles M. R., McAllister G. Expression and pharmacological characterization of the human D3 dopamine receptor. J. Pharmacol. Exp. Ther. 268:1994;417-426.
30. Gancher S., Crabbe J., Garland A., Lea E., Woodward W. Dose- and duration-dependent tolerance to rotational effects of apomorphine in a rat model of Parkinsonism. J. Pharmacol. Exp. Ther. 272:1995;275-281.
31. Gerfen C. R., Engber T. M., Mahan L. C., Susel Z., Chase T. N., Monsma F. J. Jr., Sibley D. R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432.
32. Gerfen C. R., McGinty J. F., Young W. S. III. Dopamine differentially regulates dynorphin, substance P and enkephalin expression in striatal neurons: In situ hybridisation histochemical analysis. J. Neurosci. 11:1991;1016-1031.
33. Gomez-Mancilla B., Bédard P. J. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys. Exp. Neurol. 117:1992;185-188.
34. Gomez-Mancilla B., Bédard P. J. Effect of nondopaminergic drugs onl. Clin. Neuropharm. 16:1993;418-427.
35. Graham W. C., Crossman A. R., Woodruff G. N. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat. Brain Res. 514:1990;93-102.
36. Hajji M. D., Salin P., Kerkerian-Le Goff L. Chronic dizocilpine maleate (MK-801) treatment suppresses the effects of nigrostriatal dopamine deafferentation on enkephalin but not on substance P expression in the rat striatum. Eur. J. Neurosci. 8:1996;917-926.
37. Hammond C., Feger J., Bioulac B., Souteyrand J. P. Experimental hemiballism in the monkey produced by unilateral kainic acid lesion in corpus Luysii. Brain Res. 171:1979;577-580.
38. Henry B., Crossman A. R., Brotchie J. M. Characterization of enhanced behavioural responses tol. Exp. Neurol. 151:1998;334-342.
39. Henry B., Brotchie J. M. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs Aging. 9:1996;149-158.
40. Hill M. P., Hille C. J., Maneuf Y. P., Brotchie J. M. Modulation of glutamate transmission in the basal ganglia by enadoline, a selective kappa-opioid receptor agonist, in the marmoset and rat. The Basal Ganglia. 1996;. p. 165-171.
41. Hille, C. J. M. P. Maneuf, J. M. Brotchie, Activation of delta opioid receptors inhibits GABAergic function in the globus pallidus of the rat, Exp. Neurol.
42. Hoehn M. M. Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease. Acta Neurol. Scand. 71:1985;97-106.
43. Hong J., Yang T., Gillin J., Costa E. Effects of long-term administration of antipsychotic drugs on enkephalinergic neurons. Adv. Biochem. Psychopharmacol. 24:1980;223-232.
44. Howells R. D., Kilpatrick D. L., Bhatt R., Monahan J. J., Poonian M., Udenfriend S. Molecular cloning and sequence determination of rat preproenkephalin cDNA: Sensitive probe for studying transcriptional changes in rat tissues. Proc. Natl. Acad. Sci. USA. 81:1984;7651-7655.
45. Hubble J. P., Koller W. C., Cutler N. R., Sramek J. J., Friedman J., Goetz C., Ranhosky A., Korts D., Elvin A. Pramipexole in patients with early Parkinson's disease. Clin. Neuropharmacol. 18:1995;338-347.
46. Hurtig H. I. Problems with current pharmacological treatment of Parkinson's disease. Exp. Neurol. 144:1997;10-16.
47. Inzelberg R., Nisipeanu P., Rabey M. J., Korczyn A. D. Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease. Mov. Dis. 10:1995;604-607.
48. 3. J. Neurosci. 5:1985;1513-1521.
49. Jaber M., Fournier M. C., Bloch B. Reserpine treatment stimulates enkephalin and D2 dopamine receptor gene expression in the rat striatum. Brain Res. Mol. Brain Res. 15:1992;189-194.
50. Jaber M., Normand E., Bloch B. Effect of reserpine treatment on enkephalin mRNA level in the rat striatum: An in situ hybridization study. Brain Res. Mol. Brain Res. 32:1995;156-160.
51. Jaber M., Tison F., Fournier M. C., Bloch B. Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary. Brain Res. Mol. Brain Res. 23:1994;14-20.
52. Jiang H. K., McGinty J. F., Hong J. S. Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes. Brain Res. 507:1990;57-64.
53. Kartzinel R., Teychenne P., Gillespie M. M. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Lancet. 7:1976;272-275.
54. Kashihara K., Akiyama K., Ishihara T., Shiro Y., Shohmori T. Levodopa but not bromocriptine induces AP-1 and CREB DNA-binding activity in the dopamine-depleted striatum of the rat. Life Sci. 58:1996;159-170.
55. Kincaid A. E., Penney J. B. Jr., Young A. B., Newman S. W. Evidence for a projection from the globus pallidus to the entopeduncular nucleus in the rat. Neurosci. Lett. 128:1991;121-125.
56. Koller W. C., Pahwa R. Treating motor fluctuations with controlled-release levodopa preparations. Neurology. 44:1994;S23-28.
57. Konradi C., Cole R. L., Heckers S., Hyman S. E. Amphetamine regulates gene expression in rat striatum via transcription factor CREB. J. Neurosci. 14:1994;5623-5634.
58. Krejci I., Schuh J., Pragerova H., Dlabac A. Lisuride and transdihydrolisuride: differences in action on central dopaminergic functions in dependence on the location and state of receptors. Pol. J. Pharmacol. Pharm. 37:1985;263-271.
59. Le Witt P. A., Burns R. S., Calne D. B. Lisuride treatment in Parkinson's disease: Clinical and pharmacokinetic studies. Adv. Neurol. 37:1983;131-140.
60. Le Witt P. A., Ward C. D., Larsen T. A., Raphaelson M. I., Newman R. P., Foster N., Dambrosia J. M., Calne D. B. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology. 33:1983;1009-1014.
61. Lees A. J., Stern G. M. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 44:1981;1020-1023.
62. Lees A. J. Comparison of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: Three year interim report. BMJ. 307:1993;469-472.
63. Lera G., Vaamonde J., Rodriguez M., Obeso J. A. Cabergoline in Parkinson's disease: Long-term follow-up. Neurology. 43:1993;2587-2590.
64. 1-18. Brain Res. 398:1986;390-392.
65. Li S. J., Sivam S. P., McGinty J. F., Jiang H. K., Douglass J., Calavetta L., Hong J. S. Regulation of the metabolism of striatal dynorphin by the dopaminergic system. J. Pharmacol. Exp. Ther. 246:1988;403-408.
66. Lieberman A., Kupersmith M., Estey E., Goldstein M. Treatment of Parkinson's disease with bromocriptine. N. Engl. J. Med. 295:1976;1400-1404.
67. Lieberman A. N., Kupersmith M., Gopinathan G., Estey E., Goodgold A., Goldstein M. Bromocriptine in Parkinson's disease: Further studies. Neurology. 29:1979;363-369.
68. Maneuf Y. P., Mitchell I. J., Crossman A. R., Brotchie J. M. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Res. 683:1995;102-108.
69. Maneuf Y. P., Mitchell I. J., Crossman A. R., Woodruff G. N., Brotchie J. M. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp. Neurol. 125:1994;65-71.
70. 82. J. Pharmacol. Exp. Ther. 211:1979;31-35.
71. Martin J. P. Hemichorea resulting from a local lesion of the brain (syndrome of body of Luys). Brain. 50:1927;637-651.
72. Mitchell I. J., Boyce S., Sambrook M. A., Crossman A. R. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain: Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain. 115:1992;809-824.
73. Mitchell I. J., Crossman A. R., Liminga U., Andren P., Gunne L. M. Regional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the cebus monkey. Mov. Dis. 7:1992;32-37.
74. Mitchell I. J., Jackson A., Sambrook M. A., Crossman A. R. Common neural mechanisms in experimental chorea and hemiballismus in the monkey. Evidence from 2-deoxyglucose autoradiography. Brain Res. 339:1985;346-350.
75. Mitchell I. J., Jackson A., Sambrook M. A., Crossman A. R. The role of the subthalamic nucleus in experimental chorea: Evidence from 2-deoxyglucose metabolic mapping and horseradish peroxidase tracing studies. Brain. 112:1989;1533-1548.
76. Morissette M., Goulet M., Soghomonian J. J., Blanchet P. J., Calon F., Bédard P. J., Di Paolo T. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: Comparison withl. Brain Res. Mol. Brain Res. 49:1997;55-62.
77. Newman D. D., Rajakumar N., Flumerfelt B. A., Stoessl A. J. A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease. Neuroreport. 8:1997;669-672.
78. Papa S. M., Chase T. N. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann. Neurol. 39:1996;574-578.
79. Parent A., Hazrati L. N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res. Brain Res. Rev. 20:1995;91-127.
80. Parkes J. D., Debono A. G., Marsden C. D. Bromocriptine in Parkinsonism: Long-term treatment dose response, and comparison with levodopa. J. Neurol. Neurosurg. Psychiatry. 39:1976;1101-1108.
81. Parkes J. D., Schachter M., Marsden C. D., Smith B., Wilson A. Lisuride in parkinsonism. Ann. Neurol. 9:1981;48-52.
82. Parkes J. D. Adverse effects of antiparkinsonian drugs. Drugs. 21:1981;341-353.
83. Parkes J. D. Bromocriptine in the treatment of parkinsonism. Drugs. 17:1979;365-382.
84. Paxinos G., Watson C. The Rat Brain in Stereotatic Coordinates. 1996;Academic Press, San Diego.
85. Piccini P., Weeks R. A., Brooks D. J. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann. Neurol. 42:1997;720-726.
86. Rascol O., Sabatini U., Brefel C., Fabre N., Rai S., Senard J. M., Celsis P., Viallard G., Montastruc J. L., Chollet F. Cortical motor overactivation in parkinsonian patients withl. Brain. 121:1998;527-533.
87. Rinne U. K. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: A 5-year follow-up. Neurology. 37:1987;826-828.
88. Rinne U. K. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology. 39:1989;336-339.
89. Robledo P., Feger J. Excitatory influence of rat subthalamic nucleus to substantia nigra pars reticulata and the pallidal complex: Electrophysiological data. Brain Res. 518:1990;47-54.
90. Schachter M., Bedard P., Debono A. G., Jenner P., Marsden C. D., Price P., Parkes J. D., Keenan J., Smith B., Rosenthaler J., Horowski R., Dorow R. The role of D-1 and D-2 receptors. Nature. 286:1980;157-159.
91. Schwarz J., Scheidtmann K., Trenkwalder C. Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high-doses of pergolide and cessation of levodopa. Eur. Neurol. 37:1997;236-238.
92. Shink E., Bevan M. D., Bolam J. P., Smith Y. The subthalamic nucleus and the external pallidum: Two tightly interconnected structures that control the output of the basal ganglia in the monkey. Neuroscience. 73:1996;335-357.
93. Stocchi F., Nordera G., Marsden C. D. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuation and dyskinesias. Clin. Neuropharmacol. 20:1997;95-115.
94. Tang F., Costa E., Schwartz J. P. Increase of proenkephalin mRNA and enkephalin content of rat striatum after daily injection of haloperidol for 2 to 3 weeks. Proc. Natl. Acad. Sci. USA. 80:1983;3841-3844.
95. Thomas K. L., Rose S., Jenner P., Marsden C. D. Dissociation of the striatal D-2 dopamine receptor from adenylyl cyclase following 6-hydroxydopamine-induced denervation. Biochem. Pharmacol. 44:1992;73-82.
96. Traub M., Wagner H. R., Hassan M., Jackson-Lewis V., Fahn S. The effects of chronic bromocriptine treatment on behaviour and dopamine receptor binding in the rat striatum. Eur. J. Pharmacol. 118:1985;147-154.
97. Uhl G. R., Navia B., Douglas J. Differential expression of preproenkephalin and preprodynorphin mRNA in striatal neurons: High levels of preproenkephalin expression depend on cerebral cortical afferents. J. Neurosci. 8:1988;4755-4764.
98. Verhagen Metman L., Del Dotto P., van den Munckhof B. S., Fang J., Mouradian M. M., Chase T. N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 50:1998;1323-1326.
99. Voorn P., Roest G., Groenewegen H. J. Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions. Brain Res. 412:1987;391-396.
100. Watts V. J., Neve K. A. Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors. Mol. Pharmacol. 50:1996;966-976.
101. Whittier J. R., Mettler F. A. Studies on the subthalamus of rhesus monkey. II Hyperkinesia and other physiological effects of subthalamic lesions, with special reference to the subthalamic nucleus of Luys. J. Comp. Neurol. 90:1949;319-372.
102. Yahr M. D., Duvosin R. C., Schear M. J. Treatment of parkinsonism with levodopa. Arch. Neurol. 280:1969;343-354.
103. Young W. S. III, Bonner T. I., Brann M. R. Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc. Natl. Acad. Sci. USA. 83:1986;9827-9831.